No Data
No Data
UBS Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $196
Looking Into Ascendis Pharma's Recent Short Interest
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $200
Ascendis Pharma Price Target Raised to $200.00/Share From $168.00 by JP Morgan